BiPAPgroup(19) Standardtherapy (11) Control group (15)
Anthropometric characteristics      
Age,years 55.4 ± 10.3 53.15 ± 7.68 49.75 ± 6.78
p-0.623
Men:Women 18/1 11/0 12/3
Weight, kg     144.3 ± 32.26
p-0.421
BMI, kg/m2 41.05 ± 5.95 39.06 ± 6.92 38.06 ± 7.57
p-0.485
Waist circumference, cm 134.6 ± 13.32 130.3 ± 16.29 132.16 ± 19.76
p-0.421
 Smokers (current:former:nonsmoker)   12:6:1   5:4:2 7:2:1
Sleep study characteristics      
Mild-moderateOSA (AHI <30e/h) 3/19 (16%) 2/11(18%) 0
Severe OSA (AHI >30e/h) 16/19(84%) 9/11(82%) 15/15(100%)
AHI, events/hour 50.93 ± 25.4 49.14 ± 28.3 65.94 ± 30.58
p-0.321
Sleep duration, min 211 ± 21.6 209 ± 45.9 203.5 ± 44.3
p-0.087
Time SpO2 <90%, % 79.43 ± 28.9 56.35 ± 37.8 50.43 ± 23.41
p-0.114
Lipid profiles      
HDL, mmol/l 1.20 ± 0.29 1.35 ± 0.38 1.31 ± 0.41
p-0.912
LDL, mmol/l 2.74 ± 0.75 3.38 ± 1.06 3.25 ± 1.05
p-0.428
VLDL, mmol/l 0.94 ± 0.53 0.83 ± 0.34 0.81 ± 0.25
p-0.781
Tot Chol, mmol/l 4.86 ± 1.03 5.57 ± 0.99 5.39 ± 1.28
p-0.613
Triglycerids, mmol/l 1.81 ± 0.64 1.83 ± 0.76 1.83 ± 0.56
p-0.345
Glucometabolic markers      
Fasting glucose,mmol/l 6.24 ± 2.71  4.87 ± 7.66 6.01 ± 2.1
Immunoreactive insulin, mUI/ml 18.47 ± 10.65
p*-0.316
15.3 ± 8.67
p**-0.229
19.46 ± 14.26
p***-0.151
HOMA index 4.18 ± 2.37 3.43 ± 2.48 6.01 ± 7.21
p***-0.177
HbA1C, % 6.59 ± 1.31
p*-0.253
5.92 ± 0.63
p**-0.103
6.04 ± 0.82
p***-0.210
Biomarkers      
Isoprostanespg/µml crn 0.164 ± 0.09 0.125 ± 0.05
p**-0.172
0.049 ± 0.02
p***-0.000
NT –pro-BNP pmol/ml 51.75 ± 46.3 39.12 ± 8.76
p**-0.453
-
Resistin,ng/ml 8.53 ± 7.96 4.45 ± 0.78
p**-0.375
2.51 ± 0.75
p***-0.078
FFA,mmol/l 0.189 ± 0.06 0.258 ± 0.11
p**-0.273
0.198 ± 0.10
p***-0.305
p*- Mann -Whithney comparison BiPAP vs standard; p**- Mann - Whithney comparison standard vs controls ; p***- Mann -Whithney comparison BiPAP vs controls.
Table 1: Basic characteristics of patients - p-Kruskall –Wallis comparison between three groups.